Cabaletta Bio, Inc. CABA
1.50 USD +0.20 (+15.38%)
Nov 9, 2026, 3:26 PM EST
1.37 Day range 1.55
1.28 52-week range 4.15
- YTD
- -31.51%
- 1 year
- -41.18%
News
benzinga.com Citigroup Maintains Buy on Cabaletta Bio, Lowers Price Target to $8 Citigroup analyst Samantha Semenkow maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and lowers the price target from $10 to $8.- benzinga.com Reported Sunday, Cabaletta Says Rese-Cel Delivers Immunomodulator-Free Responses Across Dermatomyositis, Lupus Nephritis And Systemic Sclerosis Through At Least One Year; Myositis BLA Planned For First Quarter Of 2028 100% (6 of 6) of dermatomyositis patients maintained immunomodulator-free, moderate-to-major TIS responses through one year, with most patients also free of steroids 100% (5 of 5) of lupus nephritis…
benzinga.com Cabaletta Bio Q3 EPS $(0.28) Beats $(0.33) Estimate Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.33) by 15.15 percent. This is a 36.36 percent increase over losses of…
globenewswire.com Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update RESET-Myositis ® registrational adult topline results anticipated in 2H27 with BLA submission in 1Q28, including Phase 1/2 juvenile dermatomyositis data for potential PRV eligibility and Phase 1/2…
globenewswire.com Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PHILADELPHIA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies…
globenewswire.com Cabaletta Bio to Participate in Upcoming Investor Conferences PHILADELPHIA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies…
benzinga.com HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $16 Price Target HC Wainwright & Co. analyst Douglas Tsao reiterates Cabaletta Bio (NASDAQ:CABA) with a Buy and maintains $16 price target.
benzinga.com Cango, Nio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Tuesday. Shares of Cango Inc (NYSE:CANG) fell sharply in pre-market trading as the company posted…
benzinga.com Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Lowers Price Target to $3 Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and lowers the price target from $4 to $3.- benzinga.com Cabaletta Bio Q2 EPS $(0.34) Beats $(0.39) Estimate Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 12.82 percent. This is a 53.42 percent increase over losses of…
- benzinga.com Cabaletta Bio Presents New Clinical Data Supporting Rese-Cel As Potential Treatment For Multiple Autoimmune Diseases, At EULAR 2026 Congress 83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through…
- benzinga.com Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Raises Price Target to $4 Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and raises the price target from $2 to $4.
- benzinga.com Cabaletta Bio Q1 EPS $(0.39), Inline Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.39) per share which met the analyst consensus estimate. This is a 45.07 percent increase over losses of $(0.71) per share from the same…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com Global Business Travel Group Posts Upbeat Q1 Results, Joins Cabaletta Bio, Aura Biosciences And Other Big Stocks Moving Higher On Monday Global Business Travel Group Inc (GBTG), a NYSE-listed company, saw its stock rise 57% on Monday after reporting better-than-expected financial results. Other top gainers included companies like…- benzinga.com Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $30 Price Target Cantor Fitzgerald analyst Josh Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $30 price target.
benzinga.com Cabaletta Prices Share Sale Of 51.73M Shares at $2.90 to Fund Autoimmune Therapy Development Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for…
benzinga.com Cabaletta Bio Doses First Two Patients Rese-cel Manufactured on Cellares' Automated Cell Shuttle Platform First two GMP doses of rese-cel manufactured on the Cell Shuttle™ met all release specifications, were delivered on time, and have been infused into patients within Cabaletta Bio's RESET™ clinical…
benzinga.com FGI Industries, Nouveau Monde Graphite And Other Big Stocks Moving Lower In Friday's Pre-Market Session Dow futures down 0.1%. FGI Industries (NASDAQ: FGI) reported mixed results for Q4, with losses of 29 cents per share beating estimates but sales missing. Stock down 7.8% in pre-market. Other stocks…
benzinga.com Pfizer To Rally More Than 34%? Here Are 10 Top Analyst Forecasts For Tuesday Analysts change ratings & price targets for HSCS, ONDS, STRO, PFE, HST, CABA, INSM, PVH. See full list & how others rate each stock.- benzinga.com Morgan Stanley Maintains Overweight on Cabaletta Bio, Lowers Price Target to $13 Morgan Stanley analyst Michael Ulz maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and lowers the price target from $14 to $13.
benzinga.com Guggenheim Maintains Buy on Cabaletta Bio, Raises Price Target to $16 Guggenheim analyst Yatin Suneja maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and raises the price target from $15 to $16.
benzinga.com Cabaletta Bio Q4 EPS $(0.40) Beats $(0.47) Estimate Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.47) by 13.98 percent. This is a 38.46 percent increase over losses of…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Why High Roller Technologies Shares Are Trading Higher By 30%; Here Are 20 Stocks Moving Premarket - benzinga.com Cabaletta Bio Announces 2026 Strategic Priorities To Advance Rese-Cel Toward 2027 BLA, Expand Automated Cellares Manufacturing, And Progress RESET Trials Across Autoimmune Diseases Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose IND amendment…
benzinga.com FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com Cantor Fitzgerald Maintains Overweight on Cabaletta Bio, Raises Price Target to $30 Cantor Fitzgerald analyst Josh Schimmer maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and raises the price target from $15 to $30.
- benzinga.com Cabaletta Bio Announces Clinical Data And Development Updates Across RESET-Myositis, RESET-SSc And RESET-SLE Trials Evaluating Rese-Cel – All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $16 Price Target HC Wainwright & Co. analyst Douglas Tsao reiterates Cabaletta Bio (NASDAQ:CABA) with a Buy and maintains $16 price target.
- benzinga.com Cabaletta Bio Reports Initial Results For Rese-cel In Pemphigus Vulgaris Without Preconditioning; Shows Complete B Cell Depletion, Rapid Reduction In Autoantibodies And Near-complete Resolution Of Clinical Symptoms In Two Of Three Refractory Patients – Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of three refractory patients; all three patients remained off immunomodulators…
- benzinga.com Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $15 Price Target Cantor Fitzgerald analyst Josh Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $15 price target.
benzinga.com Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight.- benzinga.com Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Lowers Price Target to $2 Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and lowers the price target from $3 to $2.
benzinga.com What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $25 Price Target HC Wainwright & Co. analyst Douglas Tsao reiterates Cabaletta Bio (NASDAQ:CABA) with a Buy and maintains $25 price target.
- benzinga.com Cabaletta Bio Prices $100M Public Offering Of 39.2M Shares Of Common Stock, Pre-Funded Warrants, And Accompanying Warrants Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed…
- benzinga.com Cabaletta Bio Earlier Announced Proposed Public Offering Of Securities Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Why Kaival Brands Innovations Shares Are Trading Lower By 47%? Here Are Other Stocks Moving In Friday's Mid-Day Session
- benzinga.com Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session